Adjuvant chemotherapy in completely resected non-small-cell lung cancer.
about
Can microRNAs improve the management of lung cancer patients? A clinician's perspectiveTrial on refinement of early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: the TREAT protocolLocal recurrence following lung cancer surgery: incidence, risk factors, and outcomesTopoisomerase II alpha expression and the benefit of adjuvant chemotherapy for postoperative patients with non-small cell lung cancer.Intraoperative Molecular Imaging of Lung Adenocarcinoma Can Identify Residual Tumor Cells at the Surgical MarginsVimentin regulates lung cancer cell adhesion through a VAV2-Rac1 pathway to control focal adhesion kinase activity.High Id1 expression, a generally negative prognostic factor, paradoxically predicts a favorable prognosis for adjuvant paclitaxel plus cisplatin therapy in surgically treated lung cancer patients.Pemetrexed for the treatment of non-small-cell lung cancer.Feasibility Of Administering Adjuvant Chemotherapy Of Pemetrexed Followed By Pemetrexed/oxaliplatin Immediately Post-VATS In Patients With Completely Resected NSCLCVascular endothelial-targeted therapy combined with cytotoxic chemotherapy induces inflammatory intratumoral infiltrates and inhibits tumor relapses after surgery.Cons: long-term CT-scan follow-up is not the standard of care in patients curatively treated for an early stage non-small cell lung cancer.High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications.Recent developments in the chemotherapeutic options for nonsmall cell lung cancer.Lung cancer: future directions.A randomised phase II trial of preoperative chemotherapy of cisplatin-docetaxel or docetaxel alone for clinical stage IB/II non-small-cell lung cancer results of a Japan Clinical Oncology Group trial (JCOG 0204)Mass spectrometry-based proteomic profiling of lung cancer.Randomized feasibility study of S-1 for adjuvant chemotherapy in completely resected Stage IA non-small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 0701Targeted therapy of advanced non-small cell lung cancer: the role of bevacizumab.Phase II study of docetaxel and vinorelbine as adjuvant chemotherapy for resected non-small cell lung cancersFeasibility of adjuvant chemotherapy with S-1 consisting of a 4-week administration and a two-week rest period in patients with completely resected non-small cell lung cancer.Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States.Prognostic value of pre-operative glucose-corrected maximum standardized uptake value in patients with non-small cell lung cancer after complete surgical resection and 5-year follow-up.Perspectives in adjuvant chemotherapy in NSCLC.Survival analysis of patients with stage I non-small-cell lung cancer using clinical and DNA repair pathway expression variables.[Effect of EGFR-TKI on lymphangiogenesis of lung cancer with EGFR mutation].Role of surgery for stage IIIA-N2 non-small cell lung cancer.Endogenous secretory receptor for advanced glycation end products in non-small cell lung carcinoma.The role of positron emission tomography in the diagnosis, staging and response assessment of non-small cell lung cancer.[Expression and prognostic value of VEGF-C and lymphangeogenesis in lung adenocarcinoma and squamous cell carcinoma].[Progress of lymphadenectomy on lung cancer surgery].Neoadjuvant immunotherapy for non-small cell lung cancer: can early intervention result in durable clinical benefit?
P2860
Q26999304-9D2C7132-2DA9-4F6C-99A8-3D9245835005Q28209997-34E34ACF-8C66-4BC0-B420-C9479ED2647FQ30411297-BD577BBB-D5C7-4A40-86DA-18DD39882685Q33743596-9736F2D6-B727-4967-AD53-6A5609795A79Q33808756-C4E5C866-93F2-45F2-98A6-B06533178F8CQ34577302-2CEA060B-05D8-410F-AA37-333542894636Q34956692-BC018BF6-29AF-44BE-B5E0-18BBD0E76D67Q35003631-8935A3D6-EAF7-45F9-A418-044505BD6D9AQ35667757-34D2A16F-7A15-4D7B-AF4D-307C6C62C315Q35949793-0DEEBE0F-600C-4DE5-B795-5E50D8A5CE06Q35996056-2AC64231-BB60-4732-944A-41713DC85034Q36288148-6A9F88C5-41FB-479A-85A8-B619911B388CQ36636637-193DB99E-9B50-4F65-909B-C44FD0012FD1Q36857549-C05A47FA-1982-4BF5-9854-421B3225603DQ36882714-8CF39630-F7EC-40F1-A27C-23412CE643D1Q37171914-09E248CE-3BE3-4441-9B77-201D70E70F29Q37260026-EF05D21D-238F-4119-BAA6-9213A06B506DQ37290520-D9DF7E1D-41D9-4A7A-BC49-9772F7D7D2F4Q37346454-A5A141F2-576B-40E2-A05B-7ABB05AC78D2Q37641034-D71C28C2-4DEF-4D86-A73E-98A86B6F73B0Q39443708-E2C80998-86A5-4253-953F-C0A184B7FE20Q39933893-EFCFB19C-093F-4DA2-8EC2-54A9FB1F305DQ43061648-9E0B9D5D-5F75-4496-B0E4-9929AF579864Q49799450-E2C8156F-9699-4516-B529-E13EE646CC5FQ52980191-FABDDEEA-08B8-468C-9788-747381EDB4E7Q53741620-38288484-18B4-4747-A950-B247FE46BB39Q54577822-C4C6093B-5527-4546-B284-44E4DAE1648DQ55221692-22007A8A-5E84-4771-9E73-8CAD6D2D48EFQ55429219-7CBBA000-E0EB-4F3A-B5F6-D6938C8A7C33Q55504673-9FFE9A02-95B1-4A27-8EEB-D89A753E7135Q58128666-E1BCD849-7824-4AD2-805B-7CCE15BC88F8
P2860
Adjuvant chemotherapy in completely resected non-small-cell lung cancer.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Adjuvant chemotherapy in completely resected non-small-cell lung cancer.
@ast
Adjuvant chemotherapy in completely resected non-small-cell lung cancer.
@en
type
label
Adjuvant chemotherapy in completely resected non-small-cell lung cancer.
@ast
Adjuvant chemotherapy in completely resected non-small-cell lung cancer.
@en
prefLabel
Adjuvant chemotherapy in completely resected non-small-cell lung cancer.
@ast
Adjuvant chemotherapy in completely resected non-small-cell lung cancer.
@en
P356
P1476
Adjuvant chemotherapy in completely resected non-small-cell lung cancer.
@en
P2093
Katherine M W Pisters
P304
P356
10.1200/JCO.2005.11.478
P407
P577
2005-05-01T00:00:00Z